Last reviewed · How we verify
Adcetris-Levact
At a glance
| Generic name | Adcetris-Levact |
|---|---|
| Also known as | Bendamustine, Brentuximab Vedotin |
| Sponsor | Centre Antoine Lacassagne |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma (PHASE2)
- Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient (PHASE1, PHASE2)
- Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |